Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
| 184.55 | |
| 184.55 | |
| - | |
| 184.55 | |
| 184.55 | |
| 144.8-279.7601 | |
| 18 599 M | |
| 113.1065 | |
| 97 299 K | |
| 2 736 M | |
| 0.0036 | |
| 0.67 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Sales Revenue: Slight decline of 1.3% in constant currencies for the first 9 months of 2024, totaling EUR 2,029 million. Order Intake: Increased by 8.5% in constant currencies, reaching EUR 2.326 bill...
SARTORIUS (SARTF) came out with quarterly earnings of $1.13 per share, missing the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $2.47 per share a year ago. These figures a...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
